Nanotechnology-Driven Modulation of Lipid and Glucose Dysregulation in Obesity and Diabetes
Winniefred Nankya
Department of Clinical Pharmacy Kampala International University Uganda
Email:winniefred.nankya@studwc.kiu.ac.ug
ABSTRACT
Obesity and type 2 diabetes (T2D) are major contributors to the global burden of chronic disease, with both conditions sharing common underlying mechanisms, including lipid and glucose dysregulation. Obesity, especially visceral fat accumulation, leads to insulin resistance, inflammation, and disturbed lipid metabolism, creating an environment conducive to the development of T2D. Current therapeutic strategies predominantly focus on managing blood glucose levels or reducing body weight, yet they often fail to address the root causes of lipid and glucose dysregulation. Nanotechnology presents a novel approach to treating these conditions by enabling the precise delivery of therapeutic agents that can modulate lipid metabolism and improve glucose homeostasis. By leveraging the unique properties of nanoparticles, nanocarriers can target adipose tissue, liver, muscle, and pancreas with high specificity. Nanotechnology-driven strategies can promote insulin sensitivity, reduce lipid accumulation, and restore metabolic balance, potentially offering more effective treatments for obesity-related metabolic disorders. This review explores the mechanisms by which nanotechnology can modulate lipid and glucose dysregulation in obesity and T2D. It also examines the potential benefits and challenges of translating these nanomedicines into clinical practice, highlighting the exciting opportunities for improving therapeutic outcomes in these complex diseases.
Keywords: Nanotechnology, Obesity, Type 2 Diabetes, Lipid Metabolism, Glucose Dysregulation.
CITE AS: Winniefred Nankya (2026). Nanotechnology-Driven Modulation of Lipid and Glucose Dysregulation in Obesity and Diabetes. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):61-65.
https://doi.org/10.59298/NIJSES/2026/72.6165